Literature DB >> 11173537

Second primary cancers following breast cancer in the Japanese female population.

H Tanaka1, H Tsukuma, H Koyama, Y Kinoshita, N Kinoshita, A Oshima.   

Abstract

To assess the risk of developing second primary cancers following breast cancer in Japanese females, we performed a retrospective cohort study of 2786 patients who were newly diagnosed with breast cancer at our hospital between 1970 - 1994, until the end of 1995 (average follow-up period, 8.6 years). The expected number of each second primary cancer was calculated by multiplying the number of appropriate person-years at risk by the corresponding age- and calendar period-specific cancer incidence rates for women obtained from the Osaka Cancer Registry. One hundred and seventeen patients developed a second primary cancer other than subsequent breast cancer, yielding an observed-to-expected ratio (O / E) of 1.3 [95% confidence interval (CI) = 1.1 - 1.6]. The risk for developing a second primary cancer was significantly elevated during the first year following the diagnosis of breast cancer, and decreased with the passage of time to unity. A significantly increased risk was noted for the development of ovarian cancer (O / E = 2.4, 95% CI = 1.0 - 4.6), thyroid cancer (O / E = 3.7, 95% CI = 1.5 - 7.6) and non-Hodgkin's lymphoma (NHL) (O / E = 3.5, 95% CI = 1.4 - 7.1) among the breast cancer patients compared with the general population. Patients who received hormonal therapy as the breast cancer treatment showed a significantly increased risk for ovarian cancer (O / E = 5.5, 95% CI = 1.8 - 12.9). Patients who received chemotherapy as the breast cancer treatment had an increased risk for NHL (O / E = 5.0, 95% CI = 1.6 - 11.6). These findings indicate that Japanese female patients with breast cancer had a 30% higher risk of developing a second primary cancer than the general population, the higher risk being manifested in the early period following the diagnosis of breast cancer. Medical surveillance of breast cancer patients for NHL, as well as for ovarian cancer and thyroid cancer, is required.

Entities:  

Mesh:

Year:  2001        PMID: 11173537      PMCID: PMC5926585          DOI: 10.1111/j.1349-7006.2001.tb01040.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  23 in total

1.  Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.

Authors:  D A Berry; G Parmigiani; J Sanchez; J Schildkraut; E Winer
Journal:  J Natl Cancer Inst       Date:  1997-02-05       Impact factor: 13.506

2.  Lung cancer after radiation therapy for breast cancer.

Authors:  A I Neugut; E Robinson; W C Lee; T Murray; K Karwoski; G J Kutcher
Journal:  Cancer       Date:  1993-05-15       Impact factor: 6.860

3.  Multiple primary malignant neoplasms in breast cancer patients in Israel.

Authors:  J G Schenker; R Levinsky; G Ohel
Journal:  Cancer       Date:  1984-07-01       Impact factor: 6.860

4.  Second cancer following cancer of the breast in Connecticut, 1935-82.

Authors:  E B Harvey; L A Brinton
Journal:  Natl Cancer Inst Monogr       Date:  1985-12

5.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

6.  Breast cancer as a risk factor for other primary malignant diseases. A nationwide cohort study.

Authors:  H O Adami; L Bergkvist; U Krusemo; I Persson
Journal:  J Natl Cancer Inst       Date:  1984-11       Impact factor: 13.506

7.  Second primary cancers following female breast cancer in Osaka, Japan--a population-based cohort study.

Authors:  R Murakami; T Hiyama; A Hanai; I Fujimoto
Journal:  Jpn J Clin Oncol       Date:  1987-12       Impact factor: 3.019

8.  Risk of endometrial cancer after tamoxifen treatment of breast cancer.

Authors:  F E van Leeuwen; J Benraadt; J W Coebergh; L A Kiemeney; C H Gimbrère; R Otter; L J Schouten; R A Damhuis; M Bontenbal; F W Diepenhorst
Journal:  Lancet       Date:  1994-02-19       Impact factor: 79.321

9.  Multiple primary breast and thyroid cancer.

Authors:  E Ron; R Curtis; D A Hoffman; J T Flannery
Journal:  Br J Cancer       Date:  1984-01       Impact factor: 7.640

10.  A large-scale, hospital-based case-control study of risk factors of breast cancer according to menopausal status.

Authors:  K Hirose; K Tajima; N Hamajima; M Inoue; T Takezaki; T Kuroishi; M Yoshida; S Tokudome
Journal:  Jpn J Cancer Res       Date:  1995-02
View more
  18 in total

1.  Care for Breast Cancer Survivors.

Authors:  Su Min Jeong; Sang Min Park
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis.

Authors:  Sarah M Nielsen; Michael G White; Susan Hong; Briseis Aschebrook-Kilfoy; Edwin L Kaplan; Peter Angelos; Swati A Kulkarni; Olufunmilayo I Olopade; Raymon H Grogan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02       Impact factor: 4.254

3.  Sonographic detection of thyroid cancer in breast cancer patients.

Authors:  Jeong Seon Park; Ki Keun Oh; Eun-Kyung Kim; Eun-Ju Son; Hang-Seok Chang; Soon Won Hong; Hee Jung Moon; Kyu Sung Kwack
Journal:  Yonsei Med J       Date:  2007-02-28       Impact factor: 2.759

4.  Collision metastasis of breast and thyroid carcinoma to a single cervical lymph node: report of a case.

Authors:  Hong Zeng; Chao Liu; Yun-jie Zeng; Lin Wang; Geng-biao Chen; Xi-ming Shen
Journal:  Surg Today       Date:  2012-04-07       Impact factor: 2.549

5.  Risk of second cancer after initial treatment of breast cancer: An Osaka Cancer Registry Database study.

Authors:  Yumi Kamigaki; Koji Kawakami
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

6.  Pathological confirmation of primary lung cancer following breast cancer.

Authors:  M Tennis; B Singh; A Hjerpe; M Prochazka; K Czene; P Hall; P G Shields
Journal:  Lung Cancer       Date:  2009-09-10       Impact factor: 5.705

7.  Clinicopathologic characteristics of synchronous primary thyroid cancer detected by initial staging 18F-FDG PET-CT examination in patients with underlying malignancy.

Authors:  Bo Hyun Kim; Chang Hun Lee; Seong-Jang Kim; Yun Kyung Jeon; Sang Soo Kim; Yong Ki Kim; In Ju Kim
Journal:  Thyroid       Date:  2013-07-25       Impact factor: 6.568

8.  Synchronous solid neuroendocrine breast carcinoma and abdominal lymphoma: A case report and review of the literature.

Authors:  Miguel Alonso-Ruano; Eugeni López-Bonet; Maria Victoria Huerta-Anaya; Ester Vila-Camps; Luis Bernadó; Francesc Tuca-Rodríguez; Pedro Suarez-Pumariega; Javier A Menendez
Journal:  Oncol Lett       Date:  2012-11-23       Impact factor: 2.967

9.  Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment.

Authors:  C Rubino; F de Vathaire; A Shamsaldin; M Labbe; M G Lê
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

10.  Thyroid metastasis from breast carcinoma accompanied by papillary thyroid carcinoma.

Authors:  Song-I Yang; Kwang-Kuk Park; Jeong-Hoon Kim
Journal:  Case Rep Oncol       Date:  2014-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.